search
Back to results

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping (Transfusion)

Primary Purpose

Blood Disease, Blood Transfusion, Autologous, Blood Doping

Status
Unknown status
Phase
Phase 3
Locations
Qatar
Study Type
Interventional
Intervention
Homologous Blood Transfusion
Autologous Blood Transfusion
Sponsored by
Hamad Medical Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Blood Disease

Eligibility Criteria

20 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • both genders,
  • age 20-50 years and
  • preferably physically active but no elite athletes subjected to Anti-Doping testing.

Exclusion Criteria:

  • vulnerable subjects
  • not willing to participate
  • not signing the ICF
  • patients with end-organ failure

Sites / Locations

  • Hamad Medical CorporationRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Healthy Subjects

Anemic Patients

Arm Description

Six healthy subjects will receive an ABT (Autologous Blood Transfusion)

Six patients with anemia will receive a HBT (Homologous Blood Transfusion)

Outcomes

Primary Outcome Measures

Donor DNA (# of loci with triplets or quadruplets):
Clearance Kinetics of donor DNA which is transferred during the transfusion of one bag of homologous blood will be established.
Cellular Microparticles (10^3/uL):
Clearance Kinetics of cellular microparticles which are introduced during an autologous blood transfusion and are originating from red blood cells during blood storage will be established.

Secondary Outcome Measures

Full Information

First Posted
May 6, 2018
Last Updated
August 9, 2020
Sponsor
Hamad Medical Corporation
Collaborators
World Anti-doping Agency, Anti-Doping Lab Qatar, Sidra Medical and Research Center, Laboratorio Antidoping FMSI
search

1. Study Identification

Unique Protocol Identification Number
NCT03548766
Brief Title
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
Acronym
Transfusion
Official Title
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Homologous/Autologous Blood Doping- a Transfusion Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 20, 2018 (Actual)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hamad Medical Corporation
Collaborators
World Anti-doping Agency, Anti-Doping Lab Qatar, Sidra Medical and Research Center, Laboratorio Antidoping FMSI

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.
Detailed Description
Homologous blood transfusions (HBT) and autologous blood transfusions (ABT) are abused by athletes to illegally increase their hemoglobin mass and subsequently improve oxygen transport. Anti-Doping labs use flow-cytometry to detect HBT in cheating athletes, but athletes avoid being tested positive by matching their blood for minor blood groups before transfusion. Recent publications suggest that DNA typing by Capillary Electrophoresis or RT-PCR might be an alternative way to detect this kind of doping in athletes. Unfortunately, no data exist on the clearance of DNA after transfusion of one bag of blood using this methodology. For the detection of doping with ABT, there is no direct method available and only the biological passport, a longitudinal collection of hematological parameters can indicate doping. Recently RBC Microparticles (RBC-MPs) have been described as a potential biomarker for autologous transfusion. However, also for this methodology, no data on the clearance time of RBC-MPs are available. Thus, in this World Anti-Doping Agency (WADA) approved and sponsored project. The investigators plan to perform a clinical trial in which six healthy subjects receive an ABT and six healthy subjects or patients a HBT. Blood samples will be collected before and at several time-points after transfusion. For the detection of HBT the samples will be analyzed by the official method (cytometry), and the two genotyping methods (STR and RT-PCR) to compare these different techniques and to see if DNA-typing can replace cytometry. For the ABT the collected samples will be analyzed for RBC-MPs on a cytometer dedicated for Microparticles.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Disease, Blood Transfusion, Autologous, Blood Doping, Blood Transfusion, Homologous

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy Subjects
Arm Type
Experimental
Arm Description
Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
Arm Title
Anemic Patients
Arm Type
Experimental
Arm Description
Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
Intervention Type
Biological
Intervention Name(s)
Homologous Blood Transfusion
Other Intervention Name(s)
Allogenic Blood Transfusion
Intervention Description
Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
Intervention Type
Biological
Intervention Name(s)
Autologous Blood Transfusion
Intervention Description
Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
Primary Outcome Measure Information:
Title
Donor DNA (# of loci with triplets or quadruplets):
Description
Clearance Kinetics of donor DNA which is transferred during the transfusion of one bag of homologous blood will be established.
Time Frame
12 months
Title
Cellular Microparticles (10^3/uL):
Description
Clearance Kinetics of cellular microparticles which are introduced during an autologous blood transfusion and are originating from red blood cells during blood storage will be established.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: both genders, age 20-50 years and preferably physically active but no elite athletes subjected to Anti-Doping testing. Exclusion Criteria: vulnerable subjects not willing to participate not signing the ICF patients with end-organ failure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sven C Voss
Phone
0097455481955
Email
svoss@adlqatar.qa
First Name & Middle Initial & Last Name or Official Title & Degree
Abdulqadir Nashwan
Phone
0097466473549
Email
anashwan@hamad.qa
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sven Voss
Organizational Affiliation
ADLQ
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mohamed Yassin
Organizational Affiliation
Hamad Medical Corporation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Francesco Donati
Organizational Affiliation
Laboratorio Antidoping FMSI, Rome, Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Costas Georgakopoulos
Organizational Affiliation
ADLQ
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mohammed Alsayrafi
Organizational Affiliation
ADLQ
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jean-Charles Grivel
Organizational Affiliation
Sidra Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christophe Raynaud
Organizational Affiliation
Sidra Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamad Medical Corporation
City
Doha
Country
Qatar
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamed Yassin
First Name & Middle Initial & Last Name & Degree
Sven Voss
First Name & Middle Initial & Last Name & Degree
Mohamed Yassin
First Name & Middle Initial & Last Name & Degree
Zeyd Merenkov
First Name & Middle Initial & Last Name & Degree
Saloua Hmissi
First Name & Middle Initial & Last Name & Degree
Aysha Al-Malki
First Name & Middle Initial & Last Name & Degree
Mohammad Abdulla

12. IPD Sharing Statement

Citations:
PubMed Identifier
17614019
Citation
Voss SC, Thevis M, Schinkothe T, Schanzer W. Detection of homologous blood transfusion. Int J Sports Med. 2007 Aug;28(8):633-7. doi: 10.1055/s-2007-965076. Epub 2007 Jul 5.
Results Reference
background
PubMed Identifier
18514452
Citation
Giraud S, Robinson N, Mangin P, Saugy M. Scientific and forensic standards for homologous blood transfusion anti-doping analyses. Forensic Sci Int. 2008 Jul 18;179(1):23-33. doi: 10.1016/j.forsciint.2008.04.007. Epub 2008 Jun 2.
Results Reference
background
PubMed Identifier
25331764
Citation
Krotov G, Nikitina M, Rodchenkov G. Possible cause of lack of positive samples on homologous blood transfusion. Drug Test Anal. 2014 Nov-Dec;6(11-12):1160-2. doi: 10.1002/dta.1736. Epub 2014 Oct 20.
Results Reference
background
PubMed Identifier
23618171
Citation
Donati F, Stampella A, de la Torre X, Botre F. Investigation on the application of DNA forensic human identification techniques to detect homologous blood transfusions in doping control. Talanta. 2013 Jun 15;110:28-31. doi: 10.1016/j.talanta.2013.02.042. Epub 2013 Mar 18.
Results Reference
background
PubMed Identifier
27175858
Citation
Stampella A, Di Marco S, Pirri D, de la Torre X, Botre F, Donati F. Application of DNA-based forensic analysis for the detection of homologous transfusion of whole blood and of red blood cell concentrates in doping control. Forensic Sci Int. 2016 Aug;265:204-10. doi: 10.1016/j.forsciint.2016.04.021. Epub 2016 Apr 30.
Results Reference
background
PubMed Identifier
23842898
Citation
Manokhina I, Rupert JL. A DNA-based method for detecting homologous blood doping. Anal Bioanal Chem. 2013 Dec;405(30):9693-701. doi: 10.1007/s00216-013-7122-8. Epub 2013 Jul 11.
Results Reference
background
PubMed Identifier
12036896
Citation
Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, Lamy T, Le Prise PY, Beauplet A, Bories D, Semana G, Quelvennec E. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002 Jun 15;99(12):4618-25. doi: 10.1182/blood.v99.12.4618.
Results Reference
background
PubMed Identifier
22570718
Citation
Ni W, Le Guiner C, Moullier P, Snyder RO. Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection. PLoS One. 2012;7(5):e36461. doi: 10.1371/journal.pone.0036461. Epub 2012 May 3.
Results Reference
background
PubMed Identifier
27865649
Citation
Almizraq RJ, Seghatchian J, Acker JP. Extracellular vesicles in transfusion-related immunomodulation and the role of blood component manufacturing. Transfus Apher Sci. 2016 Dec;55(3):281-291. doi: 10.1016/j.transci.2016.10.018. Epub 2016 Oct 28.
Results Reference
background
PubMed Identifier
27721707
Citation
Straat M, Boing AN, Tuip-De Boer A, Nieuwland R, Juffermans NP. Extracellular Vesicles from Red Blood Cell Products Induce a Strong Pro-Inflammatory Host Response, Dependent on Both Numbers and Storage Duration. Transfus Med Hemother. 2016 Jul;43(4):302-305. doi: 10.1159/000442681. Epub 2015 Dec 16.
Results Reference
background
PubMed Identifier
24818656
Citation
van der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, Sturk A, van Leeuwen TG, Nieuwland R. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost. 2014 Jul;12(7):1182-92. doi: 10.1111/jth.12602. Epub 2014 Jun 19.
Results Reference
background
PubMed Identifier
24511371
Citation
Nielsen MH, Beck-Nielsen H, Andersen MN, Handberg A. A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. J Extracell Vesicles. 2014 Feb 4;3. doi: 10.3402/jev.v3.20795. eCollection 2014.
Results Reference
background
PubMed Identifier
20685428
Citation
Rubin O, Crettaz D, Tissot JD, Lion N. Pre-analytical and methodological challenges in red blood cell microparticle proteomics. Talanta. 2010 Jun 30;82(1):1-8. doi: 10.1016/j.talanta.2010.04.025. Epub 2010 Apr 22.
Results Reference
background
PubMed Identifier
21231854
Citation
Rank A, Nieuwland R, Crispin A, Grutzner S, Iberer M, Toth B, Pihusch R. Clearance of platelet microparticles in vivo. Platelets. 2011;22(2):111-6. doi: 10.3109/09537104.2010.520373. Epub 2011 Jan 13.
Results Reference
background
PubMed Identifier
28474406
Citation
Voss SC, Jaganjac M, Al-Thani AM, Grivel JC, Raynaud CM, Al-Jaber H, Al-Menhali AS, Merenkov ZA, Alsayrafi M, Latiff A, Georgakopoulos C. Analysis of RBC-microparticles in stored whole blood bags - a promising marker to detect blood doping in sports? Drug Test Anal. 2017 Nov;9(11-12):1794-1798. doi: 10.1002/dta.2212. Epub 2017 Jun 20.
Results Reference
background

Learn more about this trial

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

We'll reach out to this number within 24 hrs